[Form 4] Atlassian Corporation Insider Trading Activity

Rhea-AI Filing Summary

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) filed an 8-K (Item 8.01) dated 3 July 2025 announcing a block sale under its at-the-market equity facility.

The company sold 1,550,741 common shares at an average price of $1.2981—a premium to the prior day’s close—raising ≈ $2.0 million in gross proceeds before fees. The transaction was executed for a single institutional investor by Rodman & Renshaw via the StockBlock platform and did not include any warrants or other derivative securities.

Capital from the raise bolsters near-term liquidity without adding warrant overhang, but it does increase the outstanding share count, creating dilution for existing shareholders. Management did not disclose post-issuance shares outstanding, current cash balance, or specific use of proceeds.

No other material events were reported in this filing.

Positive

• Raised approximately $2.0 million in gross proceeds, improving near-term liquidity.
• Shares were sold at a premium to the prior day’s close, indicating institutional demand.
• The offering included no warrants, eliminating additional potential dilution from derivative securities.

Negative

• Issuance of 1.55 million new shares increases the share count and dilutes existing shareholders.
• The filing does not specify the intended use of proceeds or updated cash position, reducing transparency for investors.

Insights

Equity Research Analyst

TL;DR: $2 m ATM raise at premium price improves liquidity but adds modest dilution; overall neutral impact, modestly positive signal of demand.

Classification: Neutral-to-slightly positive. Impact: Not highly material, but relevant for a micro-cap biotech.

Detail: Raising $2 m increases cash runway—important for clinical-stage companies that typically burn cash. Selling at a premium and without warrants suggests the institutional buyer has confidence and avoids future overhang. However, the 1.55 m new shares dilute existing holders; the magnitude of dilution depends on total shares outstanding, which the filing does not specify. Lack of detail on use of proceeds and cash position limits visibility. For larger-cap issuers this would be immaterial, but for a small float company it can influence liquidity and valuation multiples.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cannon-Brookes Michael

(Last) (First) (Middle)

C/O ATLASSIAN CORPORATION

350 BUSH STREET, FLOOR 13

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atlassian Corp [ TEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Co-Founder

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/07/2025		S(1)		700	D	$212.8104(2)	466,865	I	See Footnote(3)
Class A Common Stock	07/07/2025		S(1)		600	D	$211.7018(4)	466,265	I	See Footnote(3)
Class A Common Stock	07/07/2025		S(1)		2,514	D	$215.6084(5)	463,751	I	See Footnote(3)
Class A Common Stock	07/07/2025		S(1)		2,945	D	$214.6866(6)	460,806	I	See Footnote(3)
Class A Common Stock	07/07/2025		S(1)		806	D	$213.6354(7)	460,000	I	See Footnote(3)
Class A Common Stock	07/07/2025		S(1)		100	D	$216.255(8)	459,900	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.

2. This transaction was executed in multiple trades during the day at prices ranging from $212.15 to $213.13. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Shares are held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust.

4. This transaction was executed in multiple trades during the day at prices ranging from $211.12 to $212.08. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

5. This transaction was executed in multiple trades during the day at prices ranging from $215.17 to $216.16. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

6. This transaction was executed in multiple trades during the day at prices ranging from $214.17 to $215.16. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

7. This transaction was executed in multiple trades during the day at prices ranging from $213.17 to $214.13. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

8. This transaction was executed in multiple trades during the day at prices ranging from $216.20 to $216.31. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Remarks:

	/s/ Veena Bhatia, Attorney-in-Fact for Cannon-Brookes Michael	07/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did MIRA Pharmaceuticals sell on July 3 2025?

The company sold 1,550,741 common shares.

What was the average sale price of MIRA’s shares in the ATM offering?

Shares were sold at an average price of $1.2981 per share.

How much capital did MIRA raise from this transaction?

Gross proceeds totaled approximately $2.0 million before fees and expenses.

Did the equity raise include any warrants or derivatives?

No, the offering consisted solely of common stock with no warrants attached.

Who facilitated MIRA’s block sale of shares?

The trades were executed through Rodman & Renshaw via the StockBlock platform.